anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods directed to enhancing the effectiveness of IL-2 in stimulating the immune system is disclosed. According to one method, an antagonist directed against the CD25 subunit of the high-affinity IL-2 receptor complex is administered in conjunction with IL-2. The CD25 antagonist may be an anti-CD25 antibody. According to another method, an anti-IL-2 antibody is administered in conjunction with IL-2. In another method, a mutant IL-2 with diminished ability to bind the CD25 subunit of the high-affinity IL-2 receptor complex is administered. In another method, an CD4 antagonist is administered in conjunction with IL-2 in order to stimulate the immune system.
The invention discloses an antibacterial peptide mutant and application thereof. The invention provides a polypeptide (HCN 2016-01 antibacterial peptide) shown as a sequence 2 in a sequence table. The invention also protects any one of the following polypeptides: a polypeptide as set forth in any one of sequence 3 to sequence 31 of the sequence listing. The invention also provides application of the polypeptide in preparing a microbial inhibitor. The invention also provides the use of any of the polypeptides described above for inhibiting microorganisms. The invention also provides a microbial inhibitor, the active ingredient of which is any one of the polypeptides. The invention also provides an additive with the function of inhibiting microorganisms, and the active ingredient of the additive is any one of the polypeptides. The additive is food additive, feed additive, cosmetic additive or sanitary product additive. The invention has great application and popularization value.
PURPOSE: To obtain a safe anticancer medicine containing the powder of Pursatilla koreana nakai and/or the powder of Clematidis Radix as active ingredients, and exhibiting an excellent anticancer effect. CONSTITUTION: This anticancer medicine contains the powder of Pursatilla koreana nakai and/or the powder of Clematidis Radix as active ingredients. The medicine preferably further contains one or more kinds of galenicals selected from Panax schinseng Nees, Glycyrrhiza uralensis fischer et decandolle, Ulmaceae and Armeniacae Semen in addition to the above ingredients. The Pursatilla koreana nakai and/or the Clematidis Radix are used at a dry dose of 1-10 pts.wt., and the powders of the Panax schinseng Nees, Glycyrrhiza uralensis fischer et decandolle, Ulmaceae and Armeniacae Semen are used at doses of 1-5 pts.wt., respectively. The ingredients are mixed with conventional excipient, antioxidant, preservative, etc., and subsequently processed into the preparation.  The galenicals are dried and subsequently pulverized, or subjected to exudation with a solvent such as chloroform at 0 deg.C to the boiling temperature of the solvent and subsequently subjected to the evaporation of the solvent, or the extract is dissolved in water, an alcohol, etc., and subsequently used.
BACKGROUND: Population aging is an unprecedented worldwide reality, which results in a change of epidemiological profile and increased prevalence of age-related non-communicable chronic diseases (NCDs). Among age-related NCDs, systemic arterial hypertension (HPT) is the leading cause of mortality and disability worldwide and has increased prevalence, morbidity and mortality with advancing age. Increase in physical activity level through regular physical exercise is one of the main global goals for the prevention and treatment of HPT and others NCDs. Among the different exercise types and intensities, high intensity interval exercise (HIIT) showed superior benefits for reducing blood pressure (BP) and improving variables involved in the pathophysiology of HPT when compared to continuous moderate-intensity exercise (MICE). However individuals with comorbidities or injures are not capable to follow adequate intensity of both types of exercise. Heated water-based has been used as an option to facilitate the individuals adherence to exercise and positive results especially in BP levels. Despite this, little is known about the effect of HIIT or MICE in heated water-based on BP and other hemodynamic variables involved in the pathophysiology of HPT in older hypertensive individuals. PURPOSE: To evaluate the hemodynamic and autonomic response to a HIIT versus MICE session and in 12 weeks of training in older individuals with hypertension. METHODS: 60 elderly hypertensives of both genders, aged over 60 years, will be randomized in the ratio 2: 2: 1 to 12 weeks of high intensity interval training (HIIT), moderate intensity continuous (MICE) or control follow-up without exercise (CON), respectively. Exercise programs will be discontinued after 12 weeks, and individuals will be followed up for another 12 weeks. Individuals will have their physical (cardiorespiratory and muscular) and functional capacity (walking, sitting and lifting ability), hemodynamic variables (blood pressure, arterial stiffness, endothelial function and cardiovascular response to exercise) and autonomic variables (variability of heart rate) and quality of life assessed before and after 12 and 24 weeks of follow-up. Before the beginning of the follow-up, 20 elderly hypertensive patients will also have a hemodynamic response (ambulatory blood pressure, endothelial function, arterial stiffness) and autonomic (heart rate variability) to a session of HI-HEx, MI-HEx and CON evaluated and compared. The feasibility of HIIE and MICE will also be assessed over the 12 weeks of its implementation. HIIT will consisted of warm up (4 min), 21 min of 1 min high intensity exercise (level 15) and "very hard" (level 17) of the subjective Rating of Perceived Exertion Scale (RPE) alternating with 2 min of walking at intensity between "easy" (level 9) and "fairly easy" (level 11) of the RPE. MICE will performed of 4 min warm up and 26 min of walking or jogging at intensity between "fairly light" (level 11) and " somewhat hard " (level 13) of the RPE.
The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen. The transdermal cream may deliver an enhanced topical delivery flux of ketamine via a single transdermal application.
HIV cannot be eradicated and keep latent in anatomical and cellular reservoirs. In fact, patients undergoing antiretroviral treatment (ART) interruption rapidly experience plasma viral load rebound. The current alternative therapeutic strategies to antiretroviral treatment have the aim to achieve the eradication or permanent remission of plasma viral load, also known as functional cure, in the absence of ART, as occurs in persistent HIV controllers. In this scenario, new drugs associated to ART that allow the achievement of permanent plasma viral remission after ART withdrawn are needed.

The main targets of HIV infection are the memory CD4+ T-cells. This cell subset is mainly located in gut associated lymphoid tissue (GALT). These lymphocytes are recruited to the gut thanks to the expression of the integrin α4β7. The Env protein gp120 binds to α4β7 and enable the dissemination of HIV in the gut. At the same time the envelope of HIV is enriched in α4β7 coming from the plasma membrane of the host cells favoring its pathogenicity. Recently, the administration of a monoclonal antibody against α4β7 was shown to achieve significant protection for HIV transmission before and after low dose intravaginal inoculation of SIV in Rhesus Macaques. Surprisingly, long-term virological protection has been documented in SIV-infected macaques after ART interruption after administration and withdrawal of the monoclonal antibody against α4β7. The mechanisms through which this antibody has achieved the permanent remission of plasma viral load are not fully understood. The success of these findings in the simian model makes the antibody against α4β7 a good candidate as ART adjuvant with the aim to reach a functional cure and/or persistent virological remission in humans. Currently, there is a monoclonal antibody against α4β7 with known safety and security profiles in humans, this antibody is commercially available under the name of Vedolizumab. This antibody is used for the treatment of ulcerative colitis and Crohn Disease. In fact, there are already two clinical trials that are using Vedolizumab in HIV-infected patients (NCT02788175 y NCT03147859). In these clinical trials Vedolizumab is administered in the chronic phase of the infection in subjects with undetectable viral load during at least two years on ART. There are not clinical trials administering Vedolizumab in early stages of infection in naïve HIV-infected subjects for ART. Potentially, this strategy of early antibody treatment may increase the success of the therapy and decrease the time on ART of the individuals. The aim of the present clinical trial is to evaluate the safety and efficacy of Vedolizumab combined with ART to achieve permanent virological remission in naïve HIV-infected individuals after ART interruption.
Systems and methods of the present disclosure enable determining and preventing risk of human injury. Raw sensor data is received via sensors including one motion-related measurements of motion of the user. An aggregate motion value associated with a motion is determined based on a subset of the raw sensor data. A risk metric is determined based on the aggregate motion value. A dynamic risk metric is determined based on a risk metric history and the risk metric, where the dynamic risk metric is indicative of an injury risk associated with the user. A dynamic annoyance metric is determined based on a previous alert associated with the user, where the dynamic annoyance metric is indicative of an alert cadence and is customized based on user behavior. An alert is generated upon a determination that the dynamic risk metric has reached a predetermined threshold based on the dynamic annoyance metric.
Previous assessments in many countries as well in Guadeloupe were based on self-declaration. Such assessment is suspected to lead to underestimation. In addition, to our knowledge, no comparison has been done between those induced abortions and the natural miscarriages.

Illegal aspects of non-medical use of misoprostol and consequently bad self-declaration are hindrance to good assessment of the burden of such practice among patients asking for medical care at emergency unit for miscarriage or threatened miscarriage. They may also impair quality of evaluation of the relative risk associated to miscarriage threatened miscarriage induced by misoprostol compared to the same obstetrical complication without absorption of misoprostol. After a dose, misoprostol is quickly active and metabolised. It is mainly eliminated in urine. This elimination seems to be a way to increase the length of detection of the use of misoprostol. The aim of our study is to perform a detection of misoprostol in urine sample of patients hospitalised for a miscarriage or threatened miscarriage. This sample will be done during emergency cares. The study will not change the procedure of medical care of the patients during or after hospitalisation. All data will be obtained from information and result of tests normally done in such situation.
Microparticles that are designed to release their payload when exposed to acidic conditions are provided as a vehicle for drug delivery. Any therapeutic, diagnostic, or prophylatic agent may be encapsulated in a lipid-protein-sugar or polymeric matrix including a pH triggering agent to form pH triggerable microparticles. Preferably the diameter of the pH triggered microparticles ranges from 50 nm to 10 micrometers. The matrix of the particles may be prepared using any known lipid (e.g., DPPQ, protein (e.g., albumin), or sugar (e.g., lactose). The matrix of the particles may also be prepared using any synthetic polymers such as polyesters. Methods of preparing and administering the particles are provided. Methods of immunization, transfection, and gene therapy are also provided by administering pH triggerable microparticles.
A system, method, and computer-usable medium are disclosed for creating and modifying a care plan assigned to a patient in response to observed data from the patient. In one embodiment of the method, data corresponding to one or more types of biometric diagnosis is received from the patient and a care plan is prescribed for the patient. The care plan includes one or more biometric thresholds corresponding to the one or more types of biometric information and receiving one or more reported symptoms for the patient. The care plan further includes one or more conditions corresponding to the one or more reported symptoms. Upon determining that the received data satisfy at least one of the biometric thresholds and the one or more reported symptoms satisfy at least one of the one or more conditions, an event rule for modifying the care plan based on the received data and the one or more reported symptoms is identified. The care plan is then modified based on the event rule.
Described embodiments include a system, method, and computer program product. In a described system, a receiver circuit receives at least two reference images of a patient body part. Each reference image includes a respective landmark subsurface feature of the patient body part, and each imaged landmark subsurface feature has a respective spatial relationship to a respective region of a surface of the patient body part imaged during a medical examination. A feature matching circuit determines a correspondence between (x) each atlas landmark subsurface feature of the patient body part included in a landmark subsurface feature atlas and (y) each respective imaged landmark subsurface feature. A reporting circuit generates informational data reporting a depiction of an area of the surface of the patient body part by at least two adjacent imaged regions of the surface of the patient body part. A communication circuit outputs the informational data.
Subjects will receive the Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail (i.e., applied into both nostrils by spraying two times per nostril) 3 times a day from Day 1 to Day 7. Each day the study products will be self-administered at 8 am, 2 pm, and 8 pm.
Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib PO on days 1, 3, and 5 or QD on days 1-5 and cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.
BACKGROUND: The long-term effectiveness of immunotherapies against Multiple Myeloma (MM) remains elusive, demonstrated by the inevitable relapse in patients. This underscores the urgent need for an in-depth analysis of the MM tumor-immune microenvironment (TME). Hereto, a representative immunocompetent MM mouse model can offer a valuable approach to study the dynamic changes within the MM-TME and to uncover potential resistance mechanisms hampering effective and durable therapeutic strategies in MM.
METHODS: We generated a comprehensive single-cell RNA-sequencing atlas of the MM-TME in bone marrow and spleen encompassing different stages of disease, using the immunocompetent 5T33MM mouse model. Through comparative analysis, we correlated our murine dataset with the pathogenesis in MM patients by reanalyzing publicly available datasets of human bone marrow samples across various disease stages. Using flow cytometry, we validated the dynamic changes upon disease progression in the 5T33MM model. Furthermore, interesting target populations, as well as the immune-boosting anti-CD40 agonist (αCD40) therapy were tested ex vivo on murine and human primary samples and in vivo using the 5T33MM model.
RESULTS: In this study, we identified the heterogenous and dynamic changes within the TME of murine and human MM. We found that the MM-TME was characterized by an increase in T cells, accompanied with an exhausted phenotype. Although neutrophils appeared to be rather innocuous at early disease stages, they acquired a pro-tumorigenic phenotype during MM progression. Moreover, conventional dendritic cells (cDCs) showed a less activated phenotype in MM, underscoring the potential of immune-boosting therapies such as αCD40 therapy. Importantly, we provided the first pre-clinical evaluation of αCD40 therapy and demonstrated successful induction of cDC- and T-cell activation, accompanied by a significant short-term anti-tumor response.
CONCLUSIONS: This resource provides a comprehensive and detailed immune atlas of the evolution in human and murine MM disease progression. Our findings can contribute to immune-based patient stratification and facilitate the development of novel and durable (immune) therapeutic strategies in MM.
FIELD: medicine. SUBSTANCE: method involves preliminarily evaluating functional state of a patient by recording stabilization time and stability of omega-potential. Clophelinum is administered under condition of stable values of omega-potential ± 1 mV or its initial values drop before plateau segment appears during 5 min or its gradual decrease during 8-10 min, in the evening and before applying anesthesia, in addition to benzodiazepin series preparation that is given per os in the evening and in the morning and 40-60 min before anesthesia. Initial values of the characteristic lowering within the limits of 10 mV and coming to form plateau during 5-8 min, Clophelinum is additionally administered in the evening and 40-60 min before anesthesia and Dalargin is also additionally administered both in the evening and 40-60 min before anesthesia. Chaotic shifts of the characteristic value within the limits of 30 mV being observed, neuroleptic and narcotic analgesic like morphine or Promedol are additionally administered 40-60 min before operation. EFFECT: enhanced effectiveness in selecting individual mode of premedication; reduced drug doses; reduced risk of anesthesia complications. 2 tbl
TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
This arm will receive placebo, followed by Mepolizumab 100 mg. Subjects will receive placebo subcutaneously (SQ) monthly for 3 months, followed by Mepolizumab 100 mg subcutaneously (SQ) monthly for 3 months. Mepolizumab will be administered with 2 SQ injections of placebo and 1 SQ injection of Mepolizumab 100 mg to maintain blinding.
Compounds of formulae I and IA which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. These compounds are useful in the treatment of inflammatory diseases such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumour metastasis and myocardial ischemia in a mammalian patient. The compounds are also useful for the treatment of inflammatory brain diseases such as multiple sclerosis. Reference has been directed, in pursuance of section 14 of the Patents Act 1953, to specification No. 502580.
We will test our hypotheses by using a pilot study, in which we will recruit 18 chronically ill children from our clinical practice. We will obtain medical records for each patient 12 months prior to starting the study. Those patients without pre-study medical records will be studied for 12 months prior to starting GH. If we can obtain 6 months of prior medical records, then the patients will be studied for 6 months before starting GH. Anything less than 6 months will be studied for the full 12 months prior to starting GH. Patients will receive treatment with GH (0.3 mg/kg/wk) for 12 months and their growth will be compared to the year before treatment. All subjects will be followed every three months for the entire study. We will measure height and weight using a standardized stadiometer and scale, respectively, every three months during the study. From these measurements we will calculate height and weight velocity and height and weight Z score. Lean body mass (LBM) will be measured by DEXA every six months. Utilizing the stable isotope 1-\[13C\] leucine, we will measure whole body protein turnover (WBPT). Measurements of WBPT will be correlated with LBM and changes in height and weight velocity. This data will be compared to that from age matched normal children (archival data maintained by the PI). We will measure IGF-1 and the cytokines TNF-α, IL-6 and IL 10 at baseline and very six months. We will evaluate GH effects on these levels.
A single group, repeated measures design will be used to obtain repeated speech samples from 30 persons with chronic acquired apraxia of speech and aphasia. Speech samples will be elicited using commonly employed motor speech assessment protocols; an initial sample, a sample one week following the initial sample, and a sample at four weeks following the initial sample. The following measures will be obtained from the samples: percent consonants correct, percent fluent utterances, and duration of utterance. Stability of the measures will be examined.

After the preceding measures have been analyzed, a series of four, single-subject experimental designs will be conducted. Four participants with chronic aphasia and apraxia of speech will receive a new treatment for aphasia and apraxia of speech applied sequentially to two sets of experimental picture picture stimuli. Outcomes will be measured in terms of speech production (measures described above) as well as in terms of language production.
The present invention relates generally to copper salts of ion exchange materials that provide copper ions at levels suitable for use as an anti-infective agent. In certain aspects of the invention, copper salts of cellulose derivatives are provided. The copper salts of ion exchange materials may be formed using ether and ester derivatives of cellulose, such as carboxymethyl cellulose (CMC), ethylcellulose (EC), methylcellulose (MC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), hydroxyethyl methyl cellulose (HEMC), cellulose acetate, and cellulose triacetate. The present invention also relates to wound dressings having copper salts of ion exchange materials incorporated therein. The copper salts of ion exchange materials may produce an equilibrium of copper ions in a wound at a level that is therapeutically-effective for preventing infection.; Wound dressings containing copper salts of ion exchange materials may be used in accordance with methods of reducing the incidence of infection in wounds such as lacerations, abrasions, and burns. The wound dressings may also be used in accordance with methods for preventing infections in long-term wounds, such as those formed at wound drain, catheter, and ostomy entry sites. In further aspects of the invention, copper salts of ion exchange materials may be used to carry out methods of killing microorganisms, and may optionally be used in conjunction with additional anti-infective agents.